India is experiencing a dramatic shift in how weight and diabetes are being managed. With the arrival of medications like Mounjaro and Wegovy, powered by tirzepatide and semaglutide, people are not only achieving better control over blood sugar—they’re also losing weight more effectively than ever before.
But as the buzz around these GLP-1 drugs grows, researchers are quietly raising an important concern: what impact could they be having on vision?
A new study has found that these popular drugs may slightly increase the risk of optic nerve damage. Among 1.59 lakh people with type 2 diabetes using semaglutide or tirzepatide, 35 developed a condition known as NAION—a type of “eye stroke” that cuts off blood supply to the optic nerve, often resulting in sudden, irreversible vision loss.
Previously thought to be extremely rare, NAION is now estimated to affect about 1 in 2,500 patients on these medications—much higher than the earlier figure of 1 in 10,000. Another 93 people in the study experienced other optic nerve disorders.
While the numbers are still relatively small, the nature of these conditions makes them concerning. “You usually don’t know it’s happened until you’ve lost sight in one eye—and there’s no way to reverse it,” one researcher warned.
The eye concerns don’t stop there. Another large study tracking 1.85 lakh patients found a slight increase in diabetic retinopathy among users of GLP-1 drugs. But in a twist, those on these medications actually experienced fewer severe complications and needed less invasive treatment than those on older diabetes medications.
So, should patients be alarmed? Not necessarily—but doctors say it’s time for regular eye exams to become standard practice for anyone on these drugs, whether or not they have existing vision problems.
Scientists are still working to understand how these medications might be affecting the eyes. Theories range from changes in blood flow to impacts on micro-vessels in the retina and optic nerve. Until more long-term data is available, physicians are being asked to weigh the drugs’ many benefits against their potential—if rare—risks.
As GLP-1 drugs reshape India’s fight against obesity and diabetes, one thing is becoming clear: weight loss shouldn’t come at the cost of your eyesight. A simple eye screening might be the best safeguard in this next era of metabolic health.
